Skip to main content

in reply to Sheril Kirshenbaum

“Clinical trials of PfSPZ-LARC2 are scheduled for 2025 in the U.S., Germany, and Burkina Faso. These trials will evaluate the vaccine’s safety and efficacy in diverse populations”

Lo, thar be cookies on this site to keep track of your login. By clicking 'okay', you are CONSENTING to this.